Study on Palbociclib and INCMGA00012 for Treating Advanced Liposarcoma

Inclusion Criteria

• Have a diagnosis of advanced liposarcoma that has spread or cannot be surgically removed. The cancer must include a specific type called dedifferentiated liposarcoma.
• Have measurable cancer that can be tracked using standard criteria.
• Be 18 years or older.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have adequate organ and bone marrow function as shown by specific blood tests.
• Women and men must agree to use effective birth control during the study and for at least 120 days after the last dose of treatment.
• Be able to understand and sign a consent form.
• Be able to swallow tablets or capsules.
• If there are brain metastases, they must have been treated and stable for at least 3 months.

Exclusion Criteria

• Have not recovered from significant side effects of previous treatments, except for hair loss and stable nerve damage.
• Are taking other experimental drugs.
• Have previously been treated with drugs similar to palbociclib or INCMGA00012.
• Have uncontrolled illnesses, such as active infections, heart failure, or psychiatric conditions that could interfere with the study.
• Have a history of severe autoimmune diseases in the past 2 years, except for replacement therapies like insulin for diabetes.
• Have a prolonged QT interval on an ECG (QTcF greater than 450 ms for men and 470 ms for women).
• Have received a live vaccine within 30 days before starting the study.
• Have had radiation therapy within 2 weeks before starting the study.
• Have had an organ transplant, including stem-cell transplants.
• Have severe allergies to the study drugs or similar medications.
• Need to take medications that strongly affect liver enzymes involved in drug metabolism.